TuHURA Biosciences (NASDAQ:HURA – Get Free Report) was upgraded by investment analysts at Brookline Capital Management to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.
A number of other brokerages have also recently commented on HURA. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a research note on Friday, May 16th. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. One analyst has rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TuHURA Biosciences currently has an average rating of “Buy” and a consensus target price of $12.67.
View Our Latest Analysis on TuHURA Biosciences
TuHURA Biosciences Trading Down 7.1%
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).
Institutional Investors Weigh In On TuHURA Biosciences
A number of large investors have recently added to or reduced their stakes in HURA. Geode Capital Management LLC acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $1,084,000. Apollon Wealth Management LLC boosted its stake in shares of TuHURA Biosciences by 86.0% during the 1st quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company’s stock worth $371,000 after purchasing an additional 53,154 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $234,000. Squarepoint Ops LLC acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $223,000. Finally, Hurlow Wealth Management Group Inc. acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $170,000. 0.62% of the stock is owned by institutional investors and hedge funds.
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
- Five stocks we like better than TuHURA Biosciences
- Stock Market Upgrades: What Are They?
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- What is a Dividend King?
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.